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Abstract
Background: Copy number variants (CNVs) may play an important part in the development of common birth
defects such as oral clefts, and individual patients with multiple birth defects (including clefts) have been shown to
carry small and large chromosomal deletions. In this paper we investigate de novo deletions defined as DNA segments
missing in an oral cleft proband but present in both unaffected parents. We compare de novo deletion frequencies in
children of European ancestry with an isolated, non-syndromic oral cleft to frequencies in children of European
ancestry from randomly sampled trios.
Results: We identified a genome-wide significant 62 kilo base (kb) non-coding region on chromosome 7p14.1 where
de novo deletions occur more frequently among oral cleft cases than controls. We also observed wider de novo
deletions among cleft lip and palate (CLP) cases than seen among cleft palate (CP) and cleft lip (CL) cases.
Conclusions: This study presents a region where de novo deletions appear to be involved in the etiology of oral
clefts, although the underlying biological mechanisms are still unknown. Larger de novo deletions are more likely to
interfere with normal craniofacial development and may result in more severe clefts. Study protocol and sample DNA
source can severely affect estimates of de novo deletion frequencies. Follow-up studies are needed to further validate
these findings and to potentially identify additional structural variants underlying oral clefts.
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Background
Oral clefts are among the most common birth defects,
and include three anatomical defects: cleft lip (CL), cleft
lip and palate (CLP) and cleft palate (CP). Because there
are similarities in embryological and epidemiological evi-
dence [1,2], CL and CLP are often grouped together as
cleft lip with/without cleft palate (CL/P), although debate
remains about whether all three groups may have dis-
tinct etiologies [3,4]. Collectively, oral clefts represent the
most common type of craniofacial malformations [5] and
create a major public health burden for both affected chil-
dren and their families. The overall birth prevalence of
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oral clefts is estimated at 1 per 700 live births world-
wide, but there is dramatic variation across populations
and between racial and ethnic groups, in particular for
CL/P [2]. Oral clefts show strong familial aggregation, and
the recurrence risk among first degree relatives is approx-
imately 32 times greater than the general population risk
for CL/P, and approximately 56 times greater for CP [6].
Twin studies also suggest a major role for genes control-
ling risk of oral clefts with monozygotic twins showing
much higher concordance rates than dizygotic twins: 31%
versus 2% for CL/P, and 43% versus 7% for CP [7]. Normal
development of craniofacial features is a complex pro-
cess and disruption of any of numerous steps can lead to
development of oral clefts [8]. This etiologic complexity
is further supported by mounting evidence that multiple
genes or their regulatory genetic elements, in addition to
environmental influences, play a role in the etiology of
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oral clefts, although supporting evidence for relatively few
genes would be considered definitive [9-14].
Assessment of chromosomal anomalies such as
microdeletions and translocations have played an impor-
tant role in identifying genes and genomic regions under-
lying craniofacial disorders [15-23]. In particular, high
throughput technologies such as comparative genomic
hybridization (CGH) and single nucleotide polymor-
phism (SNP) arrays have gained popularity in identifying
chromosomal alterations [24,25]. Sivertsen et al. assessed
the prevalence of duplications and deletions in the 22q11
region (DiGeorge syndrome region) among Norwegian
offspring with CP, but did not detect any association [26].
Shi et al. used SNP genotyping, DNA sequencing, high-
resolution DNA microarray analysis, and long-range PCR
to characterize chromosomal deletions in 333 candidate
genes for orofacial clefting in 2,823 samples from 725
two and three generation families ascertained through a
proband with a CL/P [27]. These authors confirmed sev-
eral de novo deletions (defined as DNA segments missing
in an oral cleft proband but present in both parents in two
copies) in some of these candidate genes, in particular
SUMO1, TBX1, and TFAP2A, raising the possibility that
genes or regulatory elements contained within deleted
regions might play a role in the etiology of oral clefts.
Further, high rates of Mendelian inconsistencies were
observed in 11 different genes, suggesting the existence
of additional micro-deletions among oral cleft cases.
Family-based study designs as used by Shi et. al [27] are
a popular alternative to the more common population-
based designs (e.g. case-control studies) to assess asso-
ciations between copy number variants (CNVs) and a
disorder of interest [28-32], since investigating parents
and offspring simultaneously enables the researcher to
infer structural variants that occur de novo in the off-
spring (typically through a germline deletion). However,
while numerous methods for CNV delineation in indi-
vidual samples [33-38] or multiple independent sam-
ples [39-42] are available, only relatively few statistical
approaches for detecting de novo CNVs have been pro-
posed, and these are limited to offspring-parent trios.
PennCNV [43] is based on a hidden Markov model
(HMM), jointly modeling the unknown copy number
states in all three trio members. Maximum likelihood
methods are then employed to identify the most likely
copy number states in the father, mother and offspring,
which includes de novo deletions in the proband as
a special case. MinimumDistance [44] on the other
hand was specifically developed for detecting de novo
deletions in case-parent trios, since the computational
demands of the PennCNV joint HMM are substantial,
and false positive calls of de novo deletions remain a
concern even when the recommended quality control cor-
rections are employed [44]. MinimumDistance captures
differences in copy number estimates between the off-
spring and each parent at each locus before smoothing
and posterior calling are carried out (see Methods), which
greatly reduces technical and experimental sources of
noise such as genomic waves, probe effects and batch
effects [45,46], which are the major sources of false pos-
itive identifications in copy number analyses. Here, we
employ both MinimumDistance and PennCNV to esti-
mate and compare frequencies of de novo deletions in cleft
probands and unaffected children from trios of European
ancestry.
Results
We compared the frequencies of de novo deletions in
cleft probands and control children from trios. We iden-
tified de novo deletions in 467 cleft and 391 control trios,
and found a 62 kilo base (kb) non-coding region on
chromosome 7p14.1 where de novo deletions occurred
significantly more often among the cleft trios. Two dif-
ferent algorithms were employed to delineate de novo
deletions in the probands – MinimumDistance [44] and
PennCNV [43] – and yielded a total of 190 and 455 CNV
regions, respectively, where at least five de novo deletions
occurred in both sets of trios combined. A significantly
higher rate of de novo deletions in the cleft trios com-
pared to control trios was observed near the 38.3 MB
region on chromosome 7p14.1 (Figure 1; p = 4.3 × 10−2
and p = 1.1 × 10−3 respectively, corrected for multiple
comparisons). This exact genomic region has been previ-
ously identified as a region with high structural variation
(projects.tcag.ca/variation/), and deletions in
this area have been associated with developmental prob-
lems including craniofacial abnormalities [47-51].
The most significant association was observed in a
sub-region where MinimumDistance (PennCNV ) identi-
fied 10 (20) cleft cases with an apparent de novo dele-
tion, and none (one) among the control trios (Figure 2).
The 10 (20) case probands with de novo deletions in
this region included 6 (9) CL, 3 (6) CP, and 1 (5) CLP
cases. The nearest gene to this 7p14.1 region, about 20
kb upstream from the peak of this signal, is the T cell
receptor gamma alternate reading frame protein (TARP).
While this particular gene to our knowledge has not
been previously associated with craniofacial abnormal-
ities per se, copy number changes in T cell receptors
(including those on 7p14) have been strongly associated
with developmental problems [51]. For the 44 probes con-
tained in this segment of 7p14.1, the signal intensities
show a clear reduction among the 10 cases identified
by MinimumDistance, indicating hemizygous deletions.
These lower log R ratios were not observed in their
parents, indicating a normal DNA copy number state
(Figure 3). Sufficient DNA was available for three of the
cleft trios with an inferred hemizygous de novo deletion at
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Figure 1 The -log10 p-values (y-axis) derived from testing associations of inferred de novo deletions and oral clefts, shown by
chromosomal location (x-axis). Each point represents a de novo deletion CNV segment, delineated throughMinimumDistance [44] (lower half) or
PennCNV [43] (upper half). The dashed lines represent the genome-wide significance levels for a family-wise error rate of 5%, derived via
permutation tests. The striped vertical bands indicate the 22 autosomes interrogated.
this region. Quantitative real-time PCR confirmed a clear
copy number decrease in the child relative to his/her par-
ents (Additional file 1). While TARP is not a very strong
candidate for a causal gene per se, HOXA2 on 7p14.2 is
a functional candidate just over 1Mb away. A mutation
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Figure 2 The count of CNV components (y-axis) delineated via
MinimumDistance in the cleft lip/palate trios (green) and control
trios (yellow), as a function of genomic location (x-axis) near
7p14.1, plus the corresponding numbers delineated via
PennCNV in the cleft lip/palate trios (red) and control trios
(blue). Segments are defined as collections of probes where CNV
composition does not change in the combined trio sets. Short lines
thus represent small differences in width among de novo deletions.
The most significant association was observed in a sub-region where
MinimumDistance (PennCNV) identified 10 (20) cleft lip/palate
subjects with a de novo deletion, and none (one) in the control trios.
The nearest gene is the T cell receptor gamma alternate reading
frame protein TARP, about 20 kb away from the de novo deletions.
in HOXA2 causes microtia (deformity of the external
ear), hearing impairment and cleft palate (http://www.
omim.org/entry/604685). Though purely specula-
tive, it might be possible that a copy number variant
involving a distal enhancer might cause clefting similar to
the way an enhancer 1 Mb from SHH (sonic hedgehog)
produces preaxial polydactyly [52].
A second region of potential interest was identified by
PennCNV on chromosome 14, however, upon manual
inspection of signal intensities, this region appeared to be
a false positive result (see Additional file 1). An analy-
sis of de novo deletions called by both MinimumDistance
and PennCNV also yielded the chromome 7p14.1 locus as
the only significant finding among 90 CNV components
from 11 distinct loci that had at least 5 de novo deletions
called by both methods, with nine de novo deletions in
cleft trios compared to none in the controls (p = 0.032,
corrected for multiple comparisons). It is also notewor-
thy that among the oral cleft candidate genes examined by
Jugessur et al [11] and Shi et al [27], we only detected one
inherited deletion (in UGT1A7), and no de novo deletions
in these trios.
Another technique to infer or confirm de novo dele-
tions, based solely on genotypes, is to search for clusters
of Mendelian inconsistencies between genotypes of the
trio [27,53]. In our study however, the identified regions
on chromosome 7 were small and the corresponding
SNPs interrogated by these probes had low minor allele
frequency in our population, so no Mendelian inconsis-
tencies were observed among the trios with an inferred de
novo deletion in the proband.
Comparing the overall widths of MinimumDistance
and PennCNV inferred de novo deletions in cleft cases
and controls revealed that the estimated deletions were
substantially larger in cases than in controls. The
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Figure 3 The log R ratios (left) and B allele frequencies (right) near the identified 7p14.1 locus. The upper panels (containing the red dots)
represent the 10 oral cleft probands withMinimumDistance inferred de novo deletions at this locus, the lower panels (containing the blue dots)
show the data for the parents of these probands. For each subject (parent or proband), color was used for the markers within the inferred de novo
deletions (which differ in length between trios), gray dots were used for markers outside the deletions. The vertical gray bar indicates the segment
of markers that yielded the most significant association test. For visualization, slight horizontal jitter was applied for both plots, and vertical jitter was
applied for the B allele frequency plot.
median deletion width inferred from MinimumDistance
(PennCNV ) was 71.7 kb (61.3 kb) among controls and
102.7 kb (70.5 kb) among cases, corresponding to an
increase of 43% (15%) in median width of a deletion
among cases (Table 1). These observed differences in
widths were statistically significant (Kolmogorov-Smirnov
p-values of 1.2 × 10−4 and 2.9 × 10−3 respectively,
Wilcoxon rank-sum p-values of 1.0 × 10−4 and 5 × 10−2
respectively; see Methods). Compared to the controls,
the MinimumDistance inferred de novo deletions were
also larger when cleft types were considered individually,
increasing from CL (median 87.8 kb) to CP (95.2 kb) to
CLP (128.5 kb). For inferred de novo deletions identified
by PennCNV, we did not observe any trend of increas-
ing size by cleft type, as CP deletions (median 52.5 kb)
were smaller than apparent deletions in controls (Table 1).
However, this observation may reflect an excess number
of false positive (and mostly short) PennCNV identifica-
tions among controls, as discussed in more detail below.
Discussion
Even though all trios with at least one sample of poor data
quality were excluded (see Methods), the probe intensity
signal used to identify regions of copy number changes
was somewhat noisy, and substantially more variable
among control trios than in the oral cleft trios, resulting
in an inflated rate of called de novo deletions (i. e. likely
false positives) in the control group (Figure 4). This effect
was much more prominent in the set of de novo deletions
identified by PennCNV, consistent with a previous obser-
vation that MinimumDistance might be more robust to
false positive identifications (see Figure 2 in [44]). When
delineated via PennCNV, the control group had more
than a three-fold de novo deletion rate, and less than a
two-fold rate when de novo deletions were inferred with
MinimumDistance (Table 2). However, our statistical
procedure for inferring de novo deletions employed in
this study guards against spurious associations, and thus
type I error inflation, due to higher rates of false de novo
Table 1 Themedian width in kilo bases (kb) of de novo deletions, stratified by case status and cleft type for both
discoverymethods
Controls Clefts p CL p CP p CLP p
MD 71.7 102.7 1e-4 87.8 0.084 95.2 0.067 128.5 1e-5
PennCNV 61.3 70.5 0.051 81.1 0.006 52.5 0.923 85.7 0.041
MD: de novo deletions with coverage of at least ten markers inferred byMinimumDistance [44]; PennCNV : de novo deletions with coverage of at least ten markers
inferred by PennCNV [43]. CL: cleft lip; CP: cleft palate; CLP: cleft lip and palate. The p-values were derived using a one-sided Wilcoxon rank-sum test to assess a
potential increase in width of de novo deletions in the cleft offspring versus controls.
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Figure 4 The frequency of inferred de novo deletions per subject, inferred viaMinimumDistance (left) and PennCNV (right), shown
separately for oral cleft probands (red) and controls (blue). Subjects with five or more called de novo deletions were grouped together.
deletions called in the control trios, since we performed
a one-sided test with the alternative hypothesis that the
de novo deletion rate was larger among the cases than
controls. In contrast, a two-sided test would not protect
against this type I error inflation due to excessive false
positives among the controls (see Additional file 1). We
also note a one-sided hypothesis test would not guard
against type I error inflation if higher variability in the
control group would mask deletions. Thus, all significant
findings should be carefully inspected, and validated if
possible.
As DNA source is correlated with sample quality and
affects all CNV call rates, we assessed and found substan-
tial differences in proportions of DNA sources between
cases and controls. Around 36% of the control sam-
ples were collected either by buccal swab, mouthwash or
saliva, while only 17% of the cleft cases were extracted
this way (Table 3). Among samples passing quality con-
trol (see Methods for details), the rate of inferred de
novo deletions was much higher among samples where
DNAwas extracted from anything other than whole blood
(see Additional file 1). We conjecture that the increased
rate of called de novo deletions in the control group is
likely driven by the differences in the DNA sample collec-
tions, with MinimumDistance being more robust to this
artifact than PennCNV. Thus, for this particular study,
the MinimumDistance based statistics and comparisons
should be more reliable. We also note that false identi-
fications tend to involve very short segments of DNA,
based on fewer markers from the array. In short, false
positive identifications can skew the distribution of CNV
lengths, therefore we report the median deletion widths
here.
Conclusions
We identified a genome-wide significant 62 kb non-
coding region on chromosome 7p14.1 where de novo
deletions occurred more frequently in oral cleft cases than
control probands, adding to the evidence that structural
variants are involved in the etiology of oral clefts. This
Table 2 The total number of de novo deletions inferred (“count”) and the average number of inferred de novo deletions
per child (“average”), stratified by case status and cleft type for both discoverymethods
Controls Oral clefts CL CP CLP
MD 438 1.12 286 0.61 89 0.64 80 0.62 117 0.59
PennCNV 1,422 3.64 518 1.11 185 1.32 144 1.12 189 0.95
count average count average count average count average count average
MD: de novo deletions with coverage of at least ten markers inferred byMinimumDistance; PennCNV : de novo deletions with coverage of at least ten markers inferred
by PennCNV. CL: cleft lip; CP: cleft palate; CLP: cleft lip and palate. All differences between cleft and control counts are highly significant, assuming independence of
deletions (p < 10−6 for allMD comparisons, p < 10−40 for all PennCNV comparisons).
Younkin et al. BMC Genetics 2014, 15:24 Page 6 of 9
http://www.biomedcentral.com/1471-2156/15/24
Table 3 The total number (“count”) and relative
frequencies (“proportion”) of DNA source types among all
subjects, grouped by proband cleft/control status
Controls Oral clefts
blood 581 0.644 1139 0.828
buccal 64 0.071 125 0.091
mouthwash 50 0.055 21 0.015
saliva 207 0.229 90 0.065
count proportion count proportion
DNA source types differ significantly between cases and controls (p < 10−35).
region has been previously identified as a genomic region
containing high structural variation, and large deletions in
this region have been reported to result in developmen-
tal problems including craniofacial abnormalities [47-51].
Only 20 kb upstream from the signal peak lies the gene
coding for the T cell receptor gamma alternate reading
frame protein (TARP), adding to the existing literature
that T cell receptors can play a role in human develop-
ment. We also observed an overall increase in the width
of de novo deletions among oral cleft probands, with CLP
exhibiting wider de novo deletions than CL and CP cases.
Study protocol and sample DNA source affect estimated
frequencies of de novo deletions, and the problem of false
positive identifications remains a concern when examin-
ing the role of structural variants from genomic array data.
Methods
Samples
Case-parent trios were collected as part of an interna-
tional collaborative study in the GENEVA Consortium
[54]. These trios were ascertained through probands with
an isolated, non-syndromic oral cleft (either cleft lip, cleft
palate or cleft lip and palate) from 13 different recruitment
sites in the United States, Europe, Southeast and East Asia
[12]. Control trios were derived from small pedigrees col-
lected from rural Appalachia as part of a genome-wide
study of dental caries [55]. The DNA sources for cleft trio
samples included whole blood, buccal brush/swab, saliva,
mouthwash and dried blood spots, and varied by recruit-
ment site. DNA sources for control trios also included
whole blood, buccal brush/swab, saliva, and mouthwash.
All samples were hybridized to the Illumina Human610-
Quad Beadchip and typed at the Center for Inherited
Disease Research (CIDR) at Johns Hopkins Univer-
sity (http://www.cidr.jhmi.edu/). This research
project complies with the Helsinki Declaration and all
participating institutions provided their own institutional
review board (IRB) review and approval, in addition to
the review and approval of the Johns Hopkins School
of Public Health IRB for the collaborative analysis of
genome-wide marker data. Written informed consent was
obtained from parents of children ascertained through an
oral cleft, as well as their own consent or assent when the
proband could appropriately give such. To avoid potential
confounding due to ethnic differences (i.e. genetic back-
ground), we restricted our analysis to subjects of European
ancestry only.
Both MinimumDistance and PennCNV utilize the log
R ratios (LRRs) and B allele frequencies (BAFs) from the
Illumina Human610-Quad Beadchip probes to infer de
novo deletions. The LRR is a standardized estimate of
the probe intensity, quantifying the total number of allele
copies at each locus of interest. The BAF is a standardized
estimate for the proportion of the B allele’s contribution
to the total probe intensity, assessing the genotype at the
locus of interest. The BAF is standardized so homozy-
gous genotypes in copy neutral states (two allele copies)
have BAFs of approximately zero or one (for AA and
BB genotypes, respectively), and heterozygous AB geno-
types yield BAFs roughly equal to 0.5. Following pre-
viously established guidelines for quality control [43,44]
devised particularly to avoid excessive false positive iden-
tifications due to poor data quality, we excluded trios
for which any sample had whole genome amplified DNA
or a LRR median absolute deviation (MAD) above 0.3.
We also excluded trios with members flagged by CIDR’s
internal quality control pipeline. These data cleaning pro-
cedures yielded 467 oral cleft trios composed of 1,375
subjects, and 391 trios composed of 902 subjects as con-
trols. Aside from the CNV discovery via PennCNV, all
analyses were carried out in the statistical environment
R (http://cran.r-project.org/) using the pack-
ages DNACopy, GenomicRanges, GWASTools, IRanges,
MinimumDistance, all available as free software via the
Bioconductor project (http://www.bioconductor.
org/) [56].
Algorithms
The PennCNV algorithm for detection of de novo DNA
copy number aberrations is based on a hidden Markov
model (HMM), jointly modeling the (unknown) copy
number states in all three trio members. The state tran-
sition probabilities are based on the observed LRRs and
BAFs in the samples, and the population BAF. Maximum
likelihood methods are employed to identify the most
likely copy number states in the father, mother and off-
spring, and these are encoded as a three-digit numerical
code. A normal DNA copy number (two alleles) is des-
ignated as a 3, a hemizygous deletion (one allele copy) is
indicated as a 2, and a homozygous deletion (zero allele
copies) is indicated as a 1. Thus, de novo deletions in off-
spring with genotypic normal parents are encoded as trio
state ‘332’ (loss of one allele copy in the child) or ‘331’ (loss
of both alleles). PennCNV addresses genomic waves by
incorporating the population GC content at each marker
into the HMM.
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While the joint PennCNV HMM considers all pos-
sible copy number states including inherited deletions
(e.g. ‘322’ or ’232’), MinimumDistance was developed
specifically for detecting de novo copy number changes
since the computational demands of the joint PennCNV
HMM are substantial, and false positive identifications of
de novo deletions remain a concern even when the recom-
mended quality control procedures (including genomic
wave correction) are employed [44]. This approach, freely
available as a Bioconductor package (http://www.
bioconductor.org/), is based on the “minimum dis-
tance” statistic, capturing differences in copy number
estimates between the offspring and each parent at each
locus, making it robust to genomic waves by design.
In particular when the samples of the trio members
are hybridized on the same plate (which is the highly
recommended and commonly employed approach),
MinimumDistance is an effective approach for reducing
technical and experimental sources of noise which can
generate false positives in experimental data sets. Fol-
lowing genome-wide segmentation of these minimum
distances by circular binary segmentation [34,57] (an
extremely fast procedure), final inference regarding de
novo copy number events is based on a posterior calling
step on the inferred candidate regions.MinimumDistance
uses the same code for the trio copy number states as
PennCNV, where ‘332’ and ‘331’ represent de novo loss of
alleles in the child.
Inference
To test for association with oral cleft status, we com-
pared CNV components among cases and controls. Since
inferred deletions (required to span at least 10 probes on
the array for our analysis) typically only partially overlap
between trios, we used the IRanges package to delin-
eate the CNV components into sets of markers where no
change in copy number state occurred among any of the
cleft or control trios, defining homogeneous sets of CNV
states (see Additional file 1). For all CNV components
with a total of at least five observed de novo deletions
in the cleft and control trios combined, we performed
a one-sided Fisher’s exact test, where the alternative
hypothesis was a higher de novo deletion frequency in the
cleft probands. To correct for multiple comparisons while
simultaneously taking correlations between component
statistics into account, we performed a permutation test
by shuffling case and control status across all probands.
This procedure, based on over 100,000 permutations,
established the genome-wide significance level for a 5%
family-wise error rate at the nominal values of 2.60 and
2.83 for the –log10 p-values for MinimumDistance and
PennCNV, respectively. We also performed simulations
to compare the widths of de novo deletions in cleft
and control trios. More specifically, we simulated 10,000
quantile-quantile plots under the assumption that the
cleft and control samples came from the same distribu-
tion (see Additional file 1), and used a one sided two-
sample Kolmogorov-Smirnov test to assess a potential
increase in width of de novo deletions in the cleft off-
spring. Since non-parametric mean comparisons might
be less sensitive to subtle batch effects on deletion width,
we also carried out a one-sided Wilcoxon rank-sum test
on the observed deletion widths in the case and control
trios.
Additional file
Additional file 1: Supplementary material.
Competing interests
The authors declare no competing interests.
Authors’ contributions
SGY, RBS, HS and MMP wrote all code, performed all analyses, and generated
all tables and figures. THB and IR conceived of the study. All authors
participated in its design, coordination, and drafting of the manuscript. All
authors read and approved the final version of the manuscript.
Acknowledgements
We thank the families who participated in the studies and gratefully
acknowledge the invaluable assistance of clinical, field, and laboratory staff
who contributed to this study, in particular the Center for Oral Health Research
in Appalachia. We also gratefully acknowledge the financial support provided
by the National Institute of Health grants R03 DE021437 (SGY, IR), R01
DE016148 (MLM), and Deutsche Forschungsgemeinschaft grant SCHW
1508/3-1 (HS). The consortium for GWAS genotyping and analysis was
supported by the National Institute for Dental and Craniofacial Research
through U01 DE018993 and U01 DE018903 (THB, MLM). The International Cleft
Consortium involved many recruitment sites directed by separate
investigators: Jeffrey C. Murray (University of Iowa), Rolf Terje Lie (University of
Bergen), Allen Wilcox (NIEHS), Kare Christensen (University of Southern
Denmark), Yah-Huei Wu-Chou (Chang Gang Memorial Hospital), Vincent Yeow
(KK Women’s & Children’s Hosptial), Xiaoqian Ye (Wuhan University), Bing Shi
(Sichaun University), Samuel Chong (National University of Singapore). Part of
the original recruitment of Norwegian case–parent trios was supported by the
Intramural Research Program of the National Institute of Health, National
Institute of Environmental Health Sciences.
Author details
1Department of Biostatistics, Johns Hopkins Bloomberg School of Public
Health, Baltimore MD, USA. 2Department of Oncology, Johns Hopkins School
of Medicine, Baltimore MD, USA. 3Mathematical Institute, Heinrich Heine
University, Düsseldorf, Germany. 4Department of Epidemiology, Johns
Hopkins Bloomberg School of Public Health, Baltimore MD, USA.
5McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins School of
Medicine, Baltimore MD, USA. 6School of Dental Medicine, University of
Pittsburgh, Pittsburgh PA, USA.
Received: 13 May 2013 Accepted: 31 January 2014
Published: 14 February 2014
References
1. Mossey P, Little J: Cleft lip palate: from origin to treatment, Epidemiology of
oral clefts: an international perspective, 1st edition. New York: Oxford
University Press; 2002.
2. Mossey PA, Little J, Munger RG, Dixon MJ, Shaw WC: Cleft lip and palate.
Lancet 2009, 374(9703):1773–1785.
3. Harville EW, Wilcox AJ, Lie RT, Vindenes H, Abyholm F: Cleft lip and
palate versus cleft lip only: are they distinct defects? Am J Epidemiol
2005, 162(5):448–453.
Younkin et al. BMC Genetics 2014, 15:24 Page 8 of 9
http://www.biomedcentral.com/1471-2156/15/24
4. Forrester MB, Merz RD: Comparison of cleft lip only and cleft lip and
palate, Hawai’i, 1986-2003. Hawaii Med J 2007, 66(11):300–302.
5. Mossey P: Epidemiology underpinning research in the aetiology of
orofacial clefts. Orthod Craniofac Res 2007, 10(3):114–120.
6. Sivertsen A, Wilcox AJ, Skjaerven R, Vindenes HA, Abyholm F, Harville E,
Lie RT: Familial risk of oral clefts by morphological type and severity:
population based cohort study of first degree relatives. BMJ 2008,
336(7641):432–434.
7. Mitchell LE: Cleft lip palate: from origin to treatment, Twin, Studies in Oral
Cleft Research. USA: Oxford University Press; 2002.
8. Stanier P, Moore GE: Genetics of cleft lip and palate: syndromic genes
contribute to the incidence of non-syndromic clefts. HumMol Genet
2004, 13 Spec No 1:R73–R81.
9. Farrall M, Holder S: Familial recurrence-pattern analysis of cleft lip
with or without cleft palate. Am J HumGenet 1992, 50(2):270–277.
10. Schliekelman P, Slatkin M:Multiplex relative risk and estimation of the
number of loci underlying an inherited disease. Am J HumGenet 2002,
71(6):1369–1385.
11. Jugessur A, Shi M, Gjessing HK, Lie RT, Wilcox AJ, Weinberg CR,
Christensen K, Boyles AL, Daack-Hirsch S, Trung TN, Bille C, Lidral AC,
Murray JC: Genetic determinants of facial clefting: analysis of 357
candidate genes using two national cleft studies from Scandinavia.
PLoS One 2009, 4(4):e5385.
12. Beaty TH, Murray JC, Marazita ML, Munger RG, Ruczinski I, Hetmanski JB,
Liang KY, Wu T, Murray T, Fallin MD, Redett RA, Raymond G, Schwender H,
Jin SC, Cooper ME, Dunnwald M, Mansilla MA, Leslie E, Bullard S, Lidral AC,
Moreno LM, Menezes R, Vieira AR, Petrin A, Wilcox AJ, Lie RT, Jabs EW,
Wu-Chou YH, Chen PK, Wang H, et al.: A genome-wide association
study of cleft lip with and without cleft palate identifies risk variants
near MAFB and ABCA4. Nat Genet 2010, 42(6):525–529.
13. Dixon MJ, Marazita ML, Beaty TH, Murray JC: Cleft lip and palate:
understanding genetic and environmental influences. Nat Rev Genet
2011, 12(3):167–178.
14. Ludwig KU, Mangold E, Herms S, Nowak S, Reutter H, Paul A, Becker J,
Herberz R, AlChawa T, Nasser E, Boehmer AC, Mattheisen M, Alblas MA,
Barth S, Kluck N, Lauster C, Braumann B, Reich RH, Hemprich A, Poetzsch S,
Blaumeiser B, Daratsianos N, Kreusch T, Murray JC, Marazita ML, Ruczinski
I, Scott AF, Beaty TH, Kramer FJ, Wienker TF, et al.: Genome-wide
meta-analyses of nonsyndromic cleft lip with or without cleft palate
identify six new risk loci. Nat Genet 2012, 44(9):968–971.
15. Bocian M, Walker AP: Lip pits and deletion 1q32–41. Am JMed Genet
1987, 26(2):437–443.
16. Sander A, Schmelzle R, Murray J: Evidence for a microdeletion in
1q32-41 involving the gene responsible for Van der Woude
syndrome. HumMol Genet 1994, 3(4):575–578.
17. Sander A, Murray JC, Scherpbier-Heddema T, Buetow KH, Weissenbach J,
Zingg M, Ludwig K, Schmelzle R:Microsatellite-based fine mapping of
the Van der Woude syndrome locus to an interval of 4.1 cM
between D1S245 and D1S414. Am J HumGenet 1995, 56:310–318.
18. Brewer C, Holloway S, Zawalnyski P, Schinzel A, FitzPatrick D: A
chromosomal deletion map of humanmalformations. Am J Hum
Genet 1998, 63(4):1153–1159.
19. Brewer C, Holloway S, Zawalnyski P, Schinzel A, FitzPatrick D: A
chromosomal duplication map of malformations: regions of
suspected haplo- and triplolethality–and tolerance of segmental
aneuploidy–in humans. Am J HumGenet 1999, 64(6):1702–1708.
20. Schutte BC, Murray JC: Themany faces and factors of orofacial clefts.
HumMol Genet 1999, 8(10):1853–1859.
21. FitzPatrick DR, Carr IM, McLaren L, Leek JP, Wightman P, Williamson K,
Gautier P, McGill N, Hayward C, Firth H, Markham AF, Fantes JA, Bonthron
DT: Identification of SATB2 as the cleft palate gene on 2q32-q33.
HumMol Genet 2003, 12(19):2491–2501.
22. Alkuraya FS, Saadi I, Lund JJ, Turbe-Doan A, Morton CC, Maas RL: SUMO1
haploinsufficiency leads to cleft lip and palate. Science 2006,
313(5794):1751.
23. Benko S, Fantes JA, Amiel J, Kleinjan DJ, Thomas S, Ramsay J, Jamshidi N,
Essafi A, Heaney S, Gordon CT, McBride D, Golzio C, Fisher M, Perry P,
Abadie V, Ayuso C, Holder-Espinasse M, Kilpatrick N, Lees MM, Picard A,
Temple IK, Thomas P, Vazquez MP, Vekemans M, Crollius HR, Hastie ND,
Munnich A, Etchevers HC, Pelet A, Farlie PG, Fitzpatrick DR, Lyonnet S:
Highly conserved non-coding elements on either side of SOX9
associated with Pierre Robin sequence. Nat Genet 2009, 41(3):359–364.
24. Milunsky JM, Maher TA, Zhao G, Roberts AE, Stalker HJ, Zori RT, Burch MN,
Clemens M, Mulliken JB, Smith R, Lin AE: TFAP2Amutations result in
branchio-oculo-facial syndrome. Am J HumGenet 2008,
82(5):1171–1177.
25. Osoegawa K, Vessere GM, Utami KH, Mansilla MA, Johnson MK, Riley BM,
L’Heureux J, Pfundt R, Staaf J, van der Vliet WA, Lidral AC, Schoenmakers
EFPM, Borg A, Schutte BC, Lammer EJ, Murray JC, de Jong PJ:
Identification of novel candidate genes associated with cleft lip and
palate using array comparative genomic hybridisation. J Med Genet
2008, 45(2):81–86.
26. Sivertsen A, Lie RT, Wilcox AJ, Abyholm F, Vindenes H, Haukanes BI,
Houge G: Prevalence of duplications and deletions of the 22q11
DiGeorge syndrome region in a population-based sample of infants
with cleft palate. Am JMed Genet A 2007, 143(2):129–134.
27. Shi M, Mostowska A, Jugessur A, Johnson MK, Mansilla MA, Christensen K,
Lie RT, Wilcox AJ, Murray JC: Identification of microdeletions in
candidate genes for cleft lip and/or palate. Birth Defects Res A Clin Mol
Teratol 2009, 85:42–51.
28. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper
GM, Nord AS, Kusenda M, Malhotra D, Bhandari A, Stray SM, Rippey CF,
Roccanova P, Makarov V, Lakshmi B, Findling RL, Sikich L, Stromberg T,
Merriman B, Gogtay N, Butler P, Eckstrand K, Noory L, Gochman P, Long R,
Chen Z, Davis S, Baker C, Eichler EE, Meltzer PS, et al.: Rare structural
variants disrupt multiple genes in neurodevelopmental pathways in
schizophrenia. Science 2008, 320(5875):539–543.
29. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, Shago M,
Moessner R, Pinto D, Ren Y, Thiruvahindrapduram B, Fiebig A, Schreiber S,
Friedman J, Ketelaars CEJ, Vos YJ, Ficicioglu C, Kirkpatrick S, Nicolson R,
Sloman L, Summers A, Gibbons CA, Teebi A, Chitayat D, Weksberg R,
Thompson A, Vardy C, Crosbie V, Luscombe S, Baatjes R, et al.: Structural
variation of chromosomes in autism spectrum disorder. Am J Hum
Genet 2008, 82(2):477–488.
30. Noor A, Gianakopoulos PJ, Fernandez B, Marshall CR, Szatmari P,
Roberts W, Scherer SW, Vincent JB: Copy number variation analysis
and sequencing of the X-linkedmental retardation gene
TSPAN7/TM4SF2 in patients with autism spectrum disorder.
Psychiatr Genet 2009, 19(3):154–155.
31. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, Conroy J,
Magalhaes TR, Correia C, Abrahams BS, Almeida J, Bacchelli E, Bader GD,
Bailey AJ, Baird G, Battaglia A, Berney T, Bolshakova N, Bölte S, Bolton PF,
Bourgeron T, Brennan S, Brian J, Bryson SE, Carson AR, Casallo G, Casey J,
Chung BHY, Cochrane L, Corsello C, et al.: Functional impact of global
rare copy number variation in autism spectrum disorders. Nature
2010, 466(7304):368–372.
32. Wellcome Trust Case Control Consortium, Craddock N, Hurles ME, Cardin
N, Pearson RD, Plagnol V, Robson S, Vukcevic D, Barnes C, Conrad DF,
Giannoulatou E, Holmes C, Marchini JL, Stirrups K, Tobin MD, Wain LV,
Yau C, Aerts J, Ahmad T, Andrews TD, Arbury H, Attwood A, Auton A, Ball
SG, Balmforth AJ, Barrett JC, Barroso I, Barton A, Bennett AJ, Bhaskar S,
et al.: Genome-wide association study of, CNVs in 16,000 cases of
eight common diseases and 3,000 shared controls. Nature 2010,
464(7289):713–720.
33. Colella S, Yau C, Taylor JM, Mirza G, Butler H, Clouston P, Bassett AS,
Seller A, Holmes CC, Ragoussis J: QuantiSNP: an objective bayes
Hidden-Markov model to detect and accurately map copy number
variation using SNP genotyping data. Nucleic Acids Res 2007,
35(6):2013–2025.
34. Venkatraman ES, Olshen AB: A faster circular binary segmentation
algorithm for the analysis of array CGH data. Bioinformatics 2007,
23(6):657–663.
35. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SFA, Hakonarson H,
Bucan M: PennCNV: an integrated hidden Markov model designed
for high-resolution copy number variation detection in
whole-genome SNP genotyping data. Genome Res 2007,
17(11):1665–1674.
36. Scharpf RB, Parmigiani G, Pevsner J, Ruczinski I: Hidden Markov models
for the assessment of chromosomal alterations using
high-throughput SNP arrays. Ann Appl Stat 2008, 2(2):687–713.
Younkin et al. BMC Genetics 2014, 15:24 Page 9 of 9
http://www.biomedcentral.com/1471-2156/15/24
37. Pique-Regi R, Monso-Varona J, Ortega A, Seeger RC, Triche TJ,
Asgharzadeh S: Sparse representation and Bayesian detection of
genome copy number alterations frommicroarray data.
Bioinformatics 2008, 24(3):309–318.
38. Yau C, Papaspiliopoulos O, Roberts GO, Holmes C: Bayesian
nonparametric Hidden Markov models with application to the
analysis of copy-number-variation in mammalian genomes. J R Stat
Soc Series B Stat Methodol 2011, 73:37–57.
39. Pique-Regi R, Ortega A, Asgharzadeh S: Joint estimation of copy
number variation and reference intensities on multiple DNA arrays
using GADA. Bioinformatics 2009, 25(10):1223–1230.
40. Zöllner S: CopyMap: localization and calling of copy number
variation by joint analysis of hybridization data frommultiple
individuals. Bioinformatics 2010, 26(21):2776–2777.
41. Zhang NR, Siegmund DO, Ji H, Li JZ: Detecting simultaneous
changepoints in multiple sequences. Biometrika 2010, 97(3):631–645.
42. Picard F, Lebarbier E, Hoebeke M, Rigaill G, Thiam B, Robin S: Joint
segmentation, calling, and normalization of multiple CGH profiles.
Biostatistics 2011, 12(3):413–428.
43. Wang K, Chen Z, Tadesse MG, Glessner J, Grant SFA, Hakonarson H,
Bucan M, Li M:Modeling genetic inheritance of copy number
variations. Nucleic Acids Res 2008, 36(21):e138.
44. Scharpf RB, Beaty TH, Schwender H, Younkin SG, Scott AF, Ruczinski I: Fast
detection of de novo copy number variants from SNP arrays for
case-parent trios. BMC Bioinformatics 2012, 13:330.
45. Diskin SJ, Li M, Hou C, Yang S, Glessner J, Hakonarson H, Bucan M,
Maris JM, Wang K: Adjustment of genomic waves in signal intensities
fromwhole-genome SNP genotyping platforms. Nucleic Acids Res
2008, 36(19):e126.
46. Leek JT, Scharpf RB, Bravo HC, Simcha D, Langmead B, Johnson WE,
Geman D, Baggerly K, Irizarry RA: Tackling the widespread and critical
impact of batch effects in high-throughput data. Nat Rev Genet 2010,
11(10):733–739.
47. Wagner K, Kroisel PM, Rosenkranz W:Molecular and cytogenetic
analysis in two patients with microdeletions of 7p and Greig
syndrome: hemizygosity for PGAM2 and TCRG genes. Genomics 1990,
8(3):487–491.
48. Chotai KA, Brueton LA, van Herwerden L, Garrett C, Hinkel GK, Schinzel A,
Mueller RF, Speleman F, Winter RM: Six cases of 7p deletion: clinical,
cytogenetic, andmolecular studies. Am JMed Genet 1994,
51(3):270–276.
49. Schwarzbraun T, Windpassinger C, Ofner L, Vincent JB, Cheung J,
Scherer SW, Wagner K, Kroisel PM, Petek E: Genomic analysis of five
chromosome 7p deletion patients with Greig
cephalopolysyndactyly syndrome (GCPS). Eur J Med Genet 2006,
49(4):338–345.
50. Bilguvar K, Bydon M, Bayrakli F, Ercan-Sencicek AG, Bayri Y, Mason C,
DiLuna ML, Seashore M, Bronen R, Lifton RP, State M, Gunel M: A novel
syndrome of cerebral cavernous malformation and Greig
cephalopolysyndactyly. Laboratory investigation. J Neurosurg 2007,
107(6 Suppl):495–499.
51. Shih B, Tassabehji M, Watson JS, Bayat A: DNA copy number variations
at chromosome 7p14.1 and chromosome 14q11.2 are associated
with dupuytren’s disease: potential role for MMP andWnt signaling
pathway. Plast Reconstr Surg 2012, 129(4):921–932.
52. Lettice LA, Heaney SJH, Purdie LA, Li L, de Beer P, Oostra BA, Goode D,
Elgar G, Hill RE, de Graaff E: A long-range Shh enhancer regulates
expression in the developing limb and fin and is associated with
preaxial polydactyly. HumMol Genet 2003, 12(14):1725–1735.
53. McCarroll SA, Hadnott TN, Perry GH, Sabeti PC, Zody MC, Barrett JC,
Dallaire S, Gabriel SB, Lee C, Daly MJ, Altshuler DM, Consortium IH:
Common deletion polymorphisms in the human genome. Nat Genet
2006, 38:86–92.
54. Cornelis MC, Agrawal A, Cole JW, Hansel NN, Barnes KC, Beaty TH, Bennett
SN, Bierut LJ, Boerwinkle E, Doheny KF, Feenstra B, Feingold E, Fornage M,
Haiman CA, Harris EL, Hayes MG, Heit JA, Hu FB, Kang JH, Laurie CC, Ling
H, Manolio TA, Marazita ML, Mathias RA, Mirel DB, Paschall J, Pasquale LR,
Pugh EW, Rice JP, Udren J, et al.: The Gene, Environment Association
Studies consortium (GENEVA): maximizing the knowledge obtained
from GWAS by collaboration across studies of multiple conditions.
Genet Epidemiol 2010, 34(4):364–372.
55. Polk DE, Weyant RJ, Crout RJ, McNeil DW, Tarter RE, Thomas JG,
Marazita ML: Study protocol of the Center for Oral Health Research in
Appalachia (COHRA) etiology study. BMCOral Health 2008, 8:18.
56. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B,
Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R,
Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G,
Tierney L, Yang JYH, Zhang J: Bioconductor: open software
development for computational biology and bioinformatics.
Genome Biol 2004, 5(10):R80.
57. Olshen AB, Venkatraman ES, Lucito R, Wigler M: Circular binary
segmentation for the analysis of array-based DNA copy number
data. Biostatistics 2004, 5(4):557–572.
doi:10.1186/1471-2156-15-24
Cite this article as: Younkin et al.: A genome-wide study of de novo
deletions identifies a candidate locus for non-syndromic isolated cleft
lip/palate risk. BMC Genetics 2014 15:24.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
